Project Details
Description
A Phase 1/2, Open-Label, Single-Arm and Randomized Parallel-Group Study to Investigate the Safety and Efficacy of Autologous CD19-specific Chimeric Antigen Receptor T cells (CABA-201) Compared with Belimumab in Subjects with Active Systemic Lupus Erythem
| Status | Active |
|---|---|
| Effective start/end date | 3/26/24 → 3/25/33 |
Funding
- CABALETTA BIO, INC.
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.